USA - NASDAQ:BGLC - US0906283066 - Common Stock
The current stock price of BGLC is 5.37 USD. In the past month the price decreased by -6.12%. In the past year, price increased by 32.99%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
URI | UNITED RENTALS INC | 22.04 | 60.58B | ||
FAST | FASTENAL CO | 45.75 | 54.60B | ||
GWW | WW GRAINGER INC | 25.06 | 47.24B | ||
FERG | FERGUSON ENTERPRISES INC | 23.06 | 45.24B | ||
AER | AERCAP HOLDINGS NV | 9.83 | 20.95B | ||
FTAI | FTAI AVIATION LTD | 44.28 | 18.35B | ||
WSO.B | WATSCO INC -CL B | 30.87 | 16.31B | ||
WSO | WATSCO INC | 29.9 | 15.81B | ||
QXO | QXO INC | 128.88 | 13.89B | ||
WCC | WESCO INTERNATIONAL INC | 16.92 | 10.16B | ||
CNM | CORE & MAIN INC-CLASS A | 20.05 | 10.06B | ||
AIT | APPLIED INDUSTRIAL TECH INC | 25.74 | 9.83B |
BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2020-03-11. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
BIONEXUS GENE LAB CORP
10-2 Tower B, Vertical Business Suite, 8 Jalan Kerinchi
KUALA LUMPUR WILAYAH PERSEKUTUAN MY
Employees: 9
Phone: 13072416898
The current stock price of BGLC is 5.37 USD. The price decreased by -5.79% in the last trading session.
The exchange symbol of BIONEXUS GENE LAB CORP is BGLC and it is listed on the Nasdaq exchange.
BGLC stock is listed on the Nasdaq exchange.
BIONEXUS GENE LAB CORP (BGLC) has a market capitalization of 9.67M USD. This makes BGLC a Nano Cap stock.
BIONEXUS GENE LAB CORP (BGLC) currently has 9 employees.
BIONEXUS GENE LAB CORP (BGLC) has a support level at 5.36 and a resistance level at 5.69. Check the full technical report for a detailed analysis of BGLC support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BGLC does not pay a dividend.
BIONEXUS GENE LAB CORP (BGLC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.18).
The outstanding short interest for BIONEXUS GENE LAB CORP (BGLC) is 5.47% of its float. Check the ownership tab for more information on the BGLC short interest.
ChartMill assigns a technical rating of 6 / 10 to BGLC. When comparing the yearly performance of all stocks, BGLC is one of the better performing stocks in the market, outperforming 92.44% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to BGLC. No worries on liquidiy or solvency for BGLC as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months BGLC reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 15.25% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -15.32% | ||
ROE | -19.21% | ||
Debt/Equity | 0 |